Quanterix Announces Cost-Cutting Measures Post-Acquisition

The latest announcement is out from Quanterix ( (QTRX) ).

On July 18, 2025, Quanterix Corporation announced a plan to reduce operating costs and preserve cash through a series of terminations as part of its integration strategy following the acquisition of Akoya Biosciences, Inc. This move is expected to result in annualized cash savings of approximately $18 million, primarily through headcount reductions to be completed by the third quarter of 2025. However, the company anticipates incurring expenses of around $2.5 million for severance. The actual financial impact may vary based on several assumptions, and Quanterix has acknowledged potential risks and uncertainties that could affect the expected outcomes.

The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Spark’s Take on QTRX Stock

According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.

Quanterix faces significant challenges with profitability and cash flow, despite a strong balance sheet. The recent Akoya acquisition presents growth opportunities, but current technical indicators and financial metrics suggest caution. Strategic initiatives and cost reductions could improve future prospects, yet near-term risks remain high.

To see Spark’s full report on QTRX stock, click here.

More about Quanterix

Quanterix Corporation operates in the biotechnology industry, focusing on the development and commercialization of ultra-sensitive digital immunoassay technology. The company is known for its innovative solutions that enable researchers to detect and quantify proteins and nucleic acids at extremely low levels, which is critical for advancing precision health and diagnostics.

Average Trading Volume: 757,082

Technical Sentiment Signal: Sell

Current Market Cap: $265.5M

For detailed information about QTRX stock, go to TipRanks’ Stock Analysis page.